November 18, 2026
Health news, explained with evidence
LIVE

Experimental Blood Cancer Immunotherapy Shows Survival Benefit in Late-Stage Trial

🔬 Research 1 min read 👁 3

Sellas Life Sciences announced that its experimental immunotherapy, galinpepimut-S, met its primary endpoint in a Phase 3 trial by lowering the risk of death in acute myeloid leukemia patients.

Experimental Blood Cancer Immunotherapy Shows Survival Benefit in Late-Stage Trial🔬Research

Photo: statnews.com

Key points

  • Galinpepimut-S reduced the risk of death by 41% in a Phase 3 trial.
  • The study focused on patients with an advanced stage of acute myeloid leukemia.
  • The outcome successfully achieved the primary goal outlined by Sellas Life Sciences.

Sellas Life Sciences reported that its experimental immunotherapy, galinpepimut-S, significantly decreased the risk of death by 41% compared to standard care for patients suffering from an advanced stage of acute myeloid leukemia. According to the company, this outcome successfully met the primary objective of the Phase 3 clinical trial.

While the findings suggest a potential advancement for treating this challenging form of blood cancer, experts note that detailed trial data and peer review are necessary to fully understand the clinical impact and potential limitations of the study. Observational and early-stage findings often require broader replication before changing standard medical practices.

What to know: The experimental treatment is designed to target specific cancer antigens, though patients should always consult their healthcare providers for personal medical guidance and treatment decisions.

Source statnews.com — statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.